Merck’s $11.5bn Acceleron Buy Partially Fills Future Keytruda Revenue Gap
Deal Expands Existing Cardiovascular Portfolio
The company announced the biggest biopharma M&A deal of the year so far, but Merck will need more large deals to manage declining sales when its top-selling product faces biosimilars in 2028.
